Hainan Huluwa Pharmaceutical Group Co Ltd (605199) — Capital Reinvestment Ratio

Latest as of September 2025: 0.21x

Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has a Capital Reinvestment Ratio of 0.21x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥44.34 Million) in capital expenditures (CN¥9.15 Million). Check how tangible is Hainan Huluwa Pharmaceutical Group Co Lt's equity to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.21x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥44.34 Million
CNY

Capital Expenditures

CN¥9.15 Million
CNY

Data as of

Sep 2025
Most recent filing

Hainan Huluwa Pharmaceutical Group Co Ltd Capital Reinvestment Ratio (2016–2025)

This chart tracks Hainan Huluwa Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 9 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Hainan Huluwa Pharmaceutical Group Co Lt.

Annual Capital Reinvestment Ratio for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)

Year-by-year Capital Reinvestment Ratio for Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2025. See Hainan Huluwa Pharmaceutical Group Co Lt free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 0.61x CN¥136.85 Million CN¥83.67 Million ▼ -96.5%
2023 17.32x CN¥28.25 Million CN¥489.20 Million ▲ +953.6%
2022 1.64x CN¥238.71 Million CN¥392.32 Million ▲ +22.4%
2021 1.34x CN¥102.48 Million CN¥137.62 Million ▼ -92.5%
2020 18.01x CN¥3.30 Million CN¥59.42 Million ▲ +4355.8%
2019 0.40x CN¥144.51 Million CN¥58.40 Million ▼ -82.4%
2018 2.29x CN¥31.80 Million CN¥72.82 Million ▲ +30.7%
2017 1.75x CN¥89.96 Million CN¥157.58 Million ▲ +177.6%
2016 0.63x CN¥64.96 Million CN¥40.99 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow